title: Association between genetic polymorphisms in fibroblast growth factor (FGF)1 and FGF2 and risk of endometriosis and adenomyosis in Chinese women.
abstract: BACKGROUND
  Angiogenesis appears to be an important event in the pathophysiology of endometriosis (EM) and adenomyosis. Two angiogenic factors, fibroblast growth factor (FGF) 1 and 2, play a central role in the initiation of angiogenesis. We investigated whether FGF1 -1385A/G and FGF2 754C/G polymorphisms are associated with a risk of developing EM and adenomyosis.
  
  
  METHODS
  Genotypes were analyzed by the PCR-restriction fragment length polymorphism method in two groups of women, of Han ethnicity in north China, aged 16-55 years: (1) 421 EM patients and 421 controls; (2) 269 adenomyosis patients and 269 controls.
  
  
  RESULTS
  There was no difference in genotype distribution of the FGF1 -1385A/G polymorphism between adenomyosis cases and controls (P > 0.05), but the frequency of the A allele in EM patients was lower than that in controls (P = 0.013). Genotype and allele frequencies of the FGF2 754C/C polymorphism were significantly different in both EM and adenomyosis cases versus control groups. Compared with C/C homozygotes, the G allele (C/G + G/G) was associated with a decreased susceptibility to developing EM [odds ratio (OR) = 0.575, 95% confidence interval (CI) = 0.387-0.854] and adenomyosis (OR = 0.577, 95% CI = 0.367-0.906). Combined genotype analysis of both polymorphisms also showed differences between cases versus controls (all P < 0.001).
  
  
  CONCLUSIONS
  Our study shows for the first time that the FGF2 754C/G polymorphism may be associated with a risk of developing EM and adenomyosis in north Chinese women. Carriers of the G allele in the FGF2 gene appear to be protected from these gynecological diseases. Further studies in other populations, and of other candidate genes, are now warranted.
authors.affiliation: Department of Obstetrics and Gynaecology, Hebei Cancer Institute, Hebei Medical University, Fourth Hospital, Jiankanglu 12, Shijiazhuang 050011, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Kang
authors.forename: Shi-Zhen
authors.initials: SZ
authors.lastname: Li
authors.forename: Na
authors.initials: N
authors.lastname: Wang
authors.forename: Rong-Miao
authors.initials: RM
authors.lastname: Zhou
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Dong-Jie
authors.initials: DJ
authors.lastname: Wang
authors.forename: Xiao-Fei
authors.initials: XF
authors.lastname: Li
authors.forename: Jack
authors.initials: J
authors.lastname: Bui
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D004715:Endometriosis / Q000453:epidemiology / Q000235:genetics*; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000235:genetics*; D016222:Fibroblast Growth Factor 2 / Q000235:genetics*; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D018570:Risk Assessment
chemical_list: D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1